bluebird bio anticipates the total gross proceeds from the offering
(before deducting underwriters’ discounts and commissions and estimated
offering expenses) will be approximately
The shares are being offered by bluebird bio pursuant to an
automatically effective shelf registration statement that was previously
filed with the
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.
About bluebird bio, Inc.
With its lentiviral-based gene therapies, T cell immunotherapy expertise
and gene editing capabilities, bluebird bio has built an integrated
product platform with broad potential application to severe genetic
diseases and cancer. bluebird bio’s gene therapy clinical programs
include its Lenti-D™ product candidate, currently in a Phase 2/3 study,
called the Starbeam Study, for the treatment of cerebral
adrenoleukodystrophy, and its LentiGlobin™ product candidate, currently
in four clinical studies for the treatment of transfusion-dependent
β-thalassemia, and severe sickle cell disease. bluebird bio’s oncology
pipeline is built upon the company’s leadership in lentiviral gene
delivery and T cell engineering, with a focus on developing novel T
cell-based immunotherapies, including chimeric antigen receptor (CAR T)
and T cell receptor (TCR) therapies. bluebird bio’s lead oncology
program, bb2121, is an anti-BCMA CAR T program partnered with
Forward-Looking Statements
This release contains “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995, including
statements regarding the anticipated final terms, timing and completion
of the proposed offering, and bluebird bio’s existing product candidates
and research programs. Any forward-looking statements are based on
management’s current expectations of future events and are subject to a
number of risks and uncertainties that could cause actual results to
differ materially and adversely from those set forth in or implied by
such forward-looking statements. These risks and uncertainties include,
but are not limited to, risks and uncertainties related to market
conditions and satisfaction of customary closing conditions related to
the proposed public offering, that the preliminary results from our
clinical trials will not continue or be repeated in our ongoing clinical
trials, the risk of cessation or delay of any of the ongoing or planned
clinical studies and/or our development of our product candidates, the
risk of a delay in the enrollment of patients in our clinical studies,
risks that the current or planned clinical trials of the LentiGlobin
drug product will be insufficient to support regulatory submissions or
marketing approval in the
ACTIVE/91663001.3
View source version on businesswire.com: http://www.businesswire.com/news/home/20170627006546/en/
Source: bluebird bio, Inc.
Investor Relations
bluebird bio, Inc.
Manisha Pai,
617-245-2107
mpai@bluebirdbio.com
or
Media
Contact
bluebird bio, Inc.
Elizabeth Pingpank, 617-914-8736
epingpank@bluebirdbio.com